Skip to main navigation
Skip to main content
Skip to Footer
Sandoz Site Directory
What We Do
Partnerships and Collaborations
Access to Healthcare
Who We Are
For Novartis Investors
Doing Business Responsibly
Patients & Customers
Report Side Effects
Product Safety Notices
Information for Customers
US Press Releases & News
Working at Sandoz US
Diversity & Inclusion
Key Sandoz Biosimilar Publications
Schiestl M et al. Acceptable changes in quality attributes of glycosylated biopharmaceutical. Nature Biotechnology (2011) 29:310-312.
Lamanna WC et al. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion in Biological Therapy (2018) 18:369-379.
Cohen HP et al. Switching reference medicines to biosimilars: A systematic literature review of clinical outcomes. Drugs (2018) 78:463-478.
Cohen HP. Approval of biosimilar medicines through totality of evidence. Drug Development and Delivery. (2019) 19:40-45.
Cohen HP et al. The Importance of Countering Biosimilar Disparagement and Misinformation. BioDrugs (2020) 34:407-414.
Griffiths CEM et al. The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Brit J Derm (2017) 176;928-938.
Gascon P et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study). Support Care Cancer (2016) 24:911-925.
Blauvelt A et al. Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Brit J Derm (2018) 179:623-631.
Jeremias, S. Filgrastim Agent Is Cost-Effective in NSCLC, According to ASCO Study. Center for Biosimilars. May 31, 2020.
Jump to Comments
Switching from a Reference Biologic to a Biosimilar
Biosimilar Approval Process
You are here
© 2022 Sandoz AG
This site is intended for a US audience